CL2011000832A1 - Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades. - Google Patents

Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.

Info

Publication number
CL2011000832A1
CL2011000832A1 CL2011000832A CL2011000832A CL2011000832A1 CL 2011000832 A1 CL2011000832 A1 CL 2011000832A1 CL 2011000832 A CL2011000832 A CL 2011000832A CL 2011000832 A CL2011000832 A CL 2011000832A CL 2011000832 A1 CL2011000832 A1 CL 2011000832A1
Authority
CL
Chile
Prior art keywords
thieno
adenosine
diseases
amine
pharmaceutical composition
Prior art date
Application number
CL2011000832A
Other languages
English (en)
Inventor
J Kent Barbay
Devraj Chakravarty
Brian Christopher Shook
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2011000832A1 publication Critical patent/CL2011000832A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composición farmacéutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
CL2011000832A 2008-10-13 2011-04-13 Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades. CL2011000832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10478108P 2008-10-13 2008-10-13
US12/479,158 US20100093702A1 (en) 2008-10-13 2009-06-05 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
CL2011000832A1 true CL2011000832A1 (es) 2011-07-15

Family

ID=42099433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000832A CL2011000832A1 (es) 2008-10-13 2011-04-13 Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.

Country Status (17)

Country Link
US (1) US20100093702A1 (es)
EP (1) EP2350092A1 (es)
JP (1) JP2012505264A (es)
KR (1) KR20110071109A (es)
CN (1) CN102245614A (es)
AU (1) AU2009303694A1 (es)
BR (1) BRPI0920217A2 (es)
CA (1) CA2740406A1 (es)
CL (1) CL2011000832A1 (es)
CO (1) CO6321169A2 (es)
EA (1) EA201170563A1 (es)
EC (1) ECSP11010977A (es)
IL (1) IL212173A0 (es)
MX (1) MX2011003962A (es)
PE (1) PE20110423A1 (es)
WO (1) WO2010045006A1 (es)
ZA (1) ZA201103489B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301950B2 (en) 2009-08-21 2016-04-05 The Trustees Of The University Of Pennsylvania Adamantane analogs
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US9884832B2 (en) * 2011-12-06 2018-02-06 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza A
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP3573992B1 (en) 2017-01-26 2022-04-13 Youla S. Tsantrizos Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
US10588894B2 (en) 2017-06-21 2020-03-17 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1587597A (en) * 1996-02-16 1997-09-02 Asulab S.A. Device for charging a battery using a photovoltaic cell, and timepiece comprising same
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
RU2315053C2 (ru) * 2000-05-26 2008-01-20 Шеринг Корпорейшн ПРОИЗВОДНЫЕ 5-АМИНО-ПИРАЗОЛО-[4,3-е]-1,2,4-ТРИАЗОЛО[1,5-с]ПИРИМИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ПРИМЕНЕНИЕ И СПОСОБЫ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Also Published As

Publication number Publication date
BRPI0920217A2 (pt) 2015-12-22
JP2012505264A (ja) 2012-03-01
EA201170563A1 (ru) 2011-10-31
IL212173A0 (en) 2011-06-30
US20100093702A1 (en) 2010-04-15
PE20110423A1 (es) 2011-07-08
WO2010045006A1 (en) 2010-04-22
MX2011003962A (es) 2011-05-03
ZA201103489B (en) 2012-11-28
CA2740406A1 (en) 2010-04-22
AU2009303694A1 (en) 2010-04-22
CN102245614A (zh) 2011-11-16
KR20110071109A (ko) 2011-06-28
EP2350092A1 (en) 2011-08-03
ECSP11010977A (es) 2011-05-31
CO6321169A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
DOP2011000171A (es) Compuestos organico
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
CL2015002386A1 (es) Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
DOP2011000175A (es) Compuestos organicos
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
ECSP11011181A (es) Compuestos orgánicos
CL2009000406A1 (es) Compuestos derivados de pirrolo[2,3-b]pirazinas; y su uso en la enfermedad autoinmune, trastornos inflamatorios, trastornos proliferativos, cancer, mediados por inhibidores selectivos de la jak 3.
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
SV2006002175A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR9786A (es) Compuestos de bencimidazol-tiofeno
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
GT200600081A (es) Derivados de acetilenno
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
CR9568A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate